Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma

Neuro-Oncology

Volumn 16, Issue 12, 2014, Pages 1599-1606

  La Violette, Peter S ^a   Mickevicius, Nikolai J ^b   Cochran, Elizabeth J ^b   Rand, Scott D ^a   Connelly, Jennifer ^b   Bovi, Joseph A ^b   Malkin, Mark G ^a,b   Mueller, Wade M ^a   Schmainda, Kathleen M ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Department of Biophysics ^*  (United States)

Author keywords

ADC; Brain tumor; Diffusion; FLAIR; Glioblastoma

Indexed keywords

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN EDEMA; BRAIN NECROSIS; BRAIN TUMOR HYPERCELLULARITY; CANCER GRADING; CELL DENSITY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; EX VIVO STUDY; FEMALE; FLUID ATTENUATED INVERSION RECOVERY; FLUID ATTENUATED INVERSION RECOVERY MISMATCH; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MENINGIOMA; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; VALIDATION STUDY; VERY ELDERLY; VOXEL BASED MORPHOMETRY; WHITE MATTER; DIFFUSION; DIFFUSION WEIGHTED IMAGING; NECROSIS; PATHOLOGY; PROCEDURES;

ADULT; AGED; AGED, 80 AND OVER; BRAIN EDEMA; DIFFUSION; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GLIOMA; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NECROSIS;

EID: 84938693563     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou142     Document Type: Article

References (32)

1. P. Kleihues WC. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000.
2. De Angelis LM. Brain tumors. N Engl J Med. 2001;344(2):114-123.
3. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
4. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
5. Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg. 1997;86(3):525-531.
6. Burger PC, Dubois PJ, Schold SC Jr, et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg. 1983;58(2):159-169.
7. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys. 1992;24(1):55-57.
8. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73(15):1200-1206.
9. Di Tomaso E, Snuderl M, Kamoun WS, et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011;71(1):19-28.
10. Piao Y, Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013;19(16):4392-4403.
11. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9(1):53-60.
12. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000;43(6):828-836.
13. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24):2029-2036.
14. Hayashida Y, Hirai T, Morishita S, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol. 2006;27(7):1419-1425.
15. Manenti G, Di Roma M, Mancino S, et al. Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3T. Radiol Med. 2008;113(2):199-213.
16. Gauvain KM, McKinstry RC, Mukherjee P, et al. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol. 2001;177(2):449-454.
17. Kinoshita M, Hashimoto N, Goto T, et al. Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage. 2008;43(1):29-35.
18. Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22(6):1081-1088.
19. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538-548.
20. Kim HS, Kim SY. A prospective study on the added value of pulsed arterial spin-labeling and apparent diffusion coefficients in the grading of gliomas. AJNR Am J Neuroradiol. 2007;28(9):1693-1699.
21. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241(3):839-846.
22. Fan GG, Deng QL, Wu ZH, et al. Usefulness of diffusion/perfusionweighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading? Br J Radiol. 2006;79(944):652-658.
23. Castillo M, Smith JK, Kwock L, et al. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol. 2001;22(1):60-64.
24. Lam WW, Poon WS, Metreweli C. Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma? Clin Radiol. 2002;57(3):219-225.
25. Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. 2009;28(6):e91-e93.
26. Mong S, Ellingson BM, Nghiemphu PL, et al. Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol. 2012;33(9):1763-1770.
27. Rieger J, Bahr O, Ronellenfitsch MW, et al. Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia? J Clin Oncol. 2010;28(27):e477; author reply e478.
28. Rieger J, Bahr O, Muller K, et al. Bevacizumab-induced diffusionrestricted lesions in malignant glioma patients. J Neurooncol. 2010;99(1):49-56.
29. Gupta A, Young RJ, Karimi S, et al. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol. 2011;32(7):1301-1306.
30. La Violette PS, Cochran E, Cohen AD, et al. Reduced diffusion and perfusion in bevacizumab-induced diffusion restricted necrosis versus brain tumor hypercellularity. Proc ISMRM Salt Lake City. 2013.
31. Farid N, Almeida-Freitas DB, White NS, et al. Restriction-spectrum imaging of bevacizumab-related necrosis in a patient with GBM. Front Oncol. 2013;3:258.
32. Jeyaretna DS, Curry WT Jr, Batchelor TT, et al. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011;29(7):e159-e162.